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ORIGINAL ARTICLEIntentional and Unintentional Medication
Non-Adherence in Psoriasis: The Role of
Patients’ Medication Beliefs and Habit Strength
Rachael J. Thorneloe1,2, Christopher E.M. Griffiths2,3,4, Richard Emsley5, Darren M. Ashcroft1,6 and
Lis Cordingley4, on behalf of the British Association of Dermatologists Biologic Interventions
Register and Psoriasis Stratification to Optimise Relevant Therapy Study GroupsMedication non-adherence is a missed opportunity for therapeutic benefit. We assessed “real-world” levels of
self-reported non-adherence to conventional and biologic systemic therapies used for psoriasis and evaluated
psychological and biomedical factors associated with non-adherence using multivariable analyses. Latent
profile analysis was used to investigate whether patients can be categorized into groups with similar medi-
cation beliefs. Latent profile analysis categorizes individuals with similar profiles on a set of continuous vari-
ables into discrete groups represented by a categorical latent variable. Eight hundred and eleven patients
enrolled in the British Association of Dermatologists Biologic Interventions Register were included. Six
hundred and seventeen patients were using a self-administered systemic therapy; 22.4% were classified as
“non-adherent” (12% intentionally and 10.9% unintentionally). Patients using an oral conventional systemic
agent were more likely to be non-adherent compared to those using etanercept or adalimumab (29.2% vs.
16.4%; P  0.001). Latent profile analysis supported a three-group model; all groups held strong beliefs about
their need for systemic therapy but differed in levels of medication concerns. Group 1 (26.4% of the sample)
reported the strongest concerns, followed by Group 2 (61%), with Group 3 (12.6%) reporting the weakest
concerns. Group 1 membership was associated with intentional non-adherence (odds ratio ¼ 2.27, 95% con-
fidence interval ¼ 1.164.47) and weaker medication-taking routine or habit strength was associated with
unintentional non-adherence (odds ratio ¼ 0.92, 95% confidence interval ¼ 0.890.96). Medication beliefs and
habit strength are modifiable targets for strategies to improve adherence in psoriasis.
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Conventional systemic and biologic therapies are highly
effective in the treatment of moderate to severe psoriasis;
however, treatment effectiveness is much lower in routine
clinical practice than in clinical trials (Gelfand et al., 2012;
Iskandar et al., 2017b). Patients need to adhere to their
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article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).taken as prescribed (Nieuwlaat et al., 2014). There is a lack of
high-quality data on levels of adherence to systemic therapies
outside of clinical trials, and the factors influencing adher-
ence are largely unknown (Thorneloe et al., 2013).
Non-adherence can be intentional, where patients make a
deliberate decision not to follow the prescribed medication
regimen, such as altering the dose, timing, or frequency of their
systemic therapy. In other disease groups, patients’ beliefs
about their condition and medication are important drivers of
non-adherence (Horne et al., 2013; Leventhal et al., 2016).
Patients’ evaluations of personal need for medication for cur-
rent and future health (necessity beliefs) and concerns about
potential negative effects from treatment (concern beliefs) are
important medication beliefs that influence intentional non-
adherence, as posited by the extended Common-Sense Self-
Regulatory Model of illness (Leventhal et al., 1992) and treat-
ment (Horne and Weinman, 1999, 2002).
Non-adherence can also be unintentional, such as forget-
ting to use the medication. The strength of the patient’s
routine, or habit, for taking their medication has been shown
to influence unintentional non-adherence, especially when
the patient has been using their treatment for an extended
period of time (Danner et al., 2008; Leventhal et al., 2016;
Phillips et al., 2013; Phillips et al., 2016).
The aim of the Psoriasis Stratification to Optimise Relevant
Therapy consortium is to better understand the determinants
of treatment response to biologic therapies in psoriasis inestigative Dermatology. This is an open access
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786order to develop a clinical algorithm to help stratify people to
the most appropriate first-line biologic therapy and overcome
trial-and-error prescribing (Griffiths et al., 2015). In order to
develop this stratified approach and optimize treatment
effectiveness, it is necessary to examine non-adherence and
understand its “modifiable” risk factors. The iMAP (Investi-
gating Medication Adherence in Psoriasis) study is a large
national multi-site study collecting biomedical and psycho-
logical data from patients prescribed systemic therapies at 35
dermatology centers in England. All patients are enrolled in
the British Association of Dermatologists Biologic In-
terventions Register (BADBIR), a pharmacovigilance register
representing a “real-world” cohort of psoriasis patients using
systemic therapies (Burden et al., 2012; Iskandar et al.,
2017a).
The objectives of this study were to: (i) assess real-world
levels of intentional and unintentional non-adherence to
conventional systemic and biologic therapies used for pso-
riasis; (ii) assess whether patients can be categorized into
groups with similar medication beliefs and; (iii) examine
whether psychological and biomedical factors are associated
with non-adherence to systemic therapies. To identify the
optimal number of medication belief groups, we used latent
profile analysis (LPA), which categorizes individuals with
similar profiles on a set of continuous variables (medication
beliefs) into discrete groups or latent classes, represented by a
categorical latent variable (medication belief group).
RESULTS
Demographic, clinical, and psychological data
A total of 811 patients using a systemic therapy for the
treatment of psoriasis were included in the study (Table 1). In
the biologic cohort (64.7%, n ¼ 525), the most common
prescribed biologic was adalimumab (52.5%; n ¼ 258), fol-
lowed by ustekinumab (32.6%; n ¼ 160) and etanercept
(14.9%; n ¼ 73). In total, 75.4% (n ¼ 352) were prescribed
their first biologic therapy (biologic naı¨ve) and 7% (n ¼ 36)
were using a concomitant systemic therapy. In the conven-
tional systemic cohort (35.3%; n ¼ 286), methotrexate was
the most common (52%; n ¼ 141), followed by cyclosporine
(21.8%; n ¼ 59), acitretin (19.2%; n ¼ 52), and fumaric acid
esters (7%; n ¼ 19).
Patients in the biologic cohort were significantly more
likely to be male; have younger age of onset of psoriasis;
longer duration of disease; more likely to have a diagnosis of
inflammatory arthritis; report lower Dermatology Life Quality
Index scores at the start of their systemic therapy; have longer
duration of systemic therapy; hold stronger beliefs in the
chronicity of their psoriasis; stronger beliefs that their sys-
temic therapy is necessary and helps to control and manage
their symptoms; weaker concerns about their systemic ther-
apy and medicines in general; greater perceived under-
standing of psoriasis and its causes and triggers (coherence);
and report fewer symptoms of depression compared to those
in the conventional cohort.
Non-adherence to systemic therapies and medication-taking
habit/routine strength
Only 7.3% (n ¼ 11) of patients using ustekinumab were
classified as overall non-adherent. Ustekinumab is predomi-
nately nurse-administered in the United Kingdom and thisJournal of Investigative Dermatology (2018), Volume 138value may reflect the contrast between regular patient self-
administered and 12-weekly nurse-administered injection
in most centers.
Table 2 presents the proportion of patients classified as
non-adherent to self-administered systemic therapies; those
on ustekinumab (n ¼ 160) and those with missing biologic
treatment type (n ¼ 34) were excluded. A significant pro-
portion of patients using self-administered oral conventional
systemic or subcutaneous biologic therapies (etanercept,
adalimumab) were classified as non-adherent (22.4%; n ¼
134); 12% (n ¼ 72) were classified as intentionally and
10.9% (n ¼ 66) were classified as unintentionally non-
adherent (Table 2). A higher proportion of patients pre-
scribed an oral conventional systemic were classified as non-
adherent compared to those prescribed etanercept or adali-
mumab (29.2% [n ¼ 82] vs. 16.4% [n ¼ 52]; p  0.001).
Figure 1 presents the proportion of patients classified as
overall non-adherent within the oral conventional systemic
and self-administered biologic cohorts. Fumaric acid esters
were excluded from Figure 1 due to small sample size (7%;
n ¼ 19). As shown in Figure 1, a higher proportion of patients
prescribed etanercept were classified as non-adherent
compared with adalimumab. A higher proportion of pa-
tients prescribed cyclosporine were classified as non-
adherent compared with acitretin or methotrexate.
Using the Self-Report Habit Index (Verplanken and Orbell,
2003), patients using a self-administered systemic therapy
reported strong routine, or habit, for taking their systemic
therapy, with a mean  standard deviation score of 41.5 
9.7 out of a possible score of 60. A high proportion of the
sample agreed or strongly agreed that taking their systemic
therapy is something they do “frequently” (91.2%, n ¼ 542),
“automatically” (85.2%, n ¼ 509), and “as part of their
routine” (83.7%, n ¼ 498).
Medication belief groups
The optimal number of medication belief groups was
identified using LPA. The model fit statistics for 1- to 5-class
solutions indicated a 3-class solution was optimal
(Supplementary Table S1 online); patients can be classified
into three groups characterized by distinct medication be-
liefs. Sample means (95% confidence intervals [CIs]) of
medication beliefs for the 3-class solution are presented in
Figure 2.
Each of the three medication belief groups perceived a
strong need for their systemic therapy (specific necessity) and
believed that their therapy was effective in managing their
psoriasis symptoms (treatment controllability), but differed in
their level of medication concerns.
Group 1 (26.4%; n ¼ 213) was labeled “strongly con-
cerned.” Patients in this group reported the strongest concerns
about their systemic therapy, these included potential long-
term adverse effects and future medication dependency.
Patients believed they lacked understanding about their sys-
temic therapy. Those in Group 1 also reported the strongest
concerns about the overuse of medicines in general: patients
believed that doctors use too many, and place too much trust
on medicines, and that doctors would prescribe fewer med-
icines if they had more time with patients. Patients also re-
ported the strongest concerns about the harmfulness of
Table 1. Demographic, clinical, and psychological data at baseline (n [ 811)
Characteristics
Total Sample
(n [ 811)
Conventional Cohort1
(35.3%, n [ 286)
Biologic Cohort2
(64.7%, n [ 525) P-Value3
Demographic
Age, y, mean  SD 48.1  13.1 48.4  13.7 47.9  12.8 0.599
n 720 254 466
Male, % (n) 57.1 (411) 49.2 (125) 61.4 (286) 0.002
n 720 254 466
Disease
Age of onset, y, mean  SD 25.4  15.1 27.8  16.8 24.1  13.9 0.001
n 716 252 464
Disease duration, y, mean  SD 23.3  13.8 21.3  14.8 24.3  13.0 0.004
n 718 253 465
PASI at the start of treatment, mean  SD 14.3  7.0 14.8  7.5 14.0  6.7 0.164
n 693 245 448
DLQI at the start of treatment, mean  SD 13.7  7.9 15.6  6.3 12.6  8.5 £0.001
n 684 244 440
Comorbidities
Presence of 1 comorbidity,4 % (n) 65.2 (471) 62 (158) 67 (313) 0.172
n 722 255 467
Inflammatory arthritis, % (n) 17.3 (124) 9.5 (24) 21.5 (100) £0.001
n 718 253 465
Treatment
Treatment duration, mo, mean  SD 11.4  13.5 7.0  11.1 13.9  14.1 £0.001
n 744 265 479
Psychological distress (HADS5)
Anxiety, mean  SD 6.7  4.3 6.9  4.4 6.5  4.3 0.168
n 794 281 513
Depression, mean  SD 4.8  4.0 5.3  4.2 4.5  3.9 0.010
n 796 280 516
Illness beliefs and emotional response toward psoriasis (IPQ-R6)
Illness identity7 (symptoms), mean  SD 4.2  2.8 4.1  2.6 4.3  2.9 0.420
n 784 275 509
Timeline acute/chronic, mean  SD 4.2  0.6 4.2  0.6 4.3  0.6 0.020
n 796 279 517
Timeline cyclical, mean  SD 3.3  0.7 3.3  0.7 3.2  0.7 0.080
n 803 284 519
Consequences, mean  SD 3.7  0.7 3.6  0.7 3.7  0.7 0.113
n 804 286 518
Personal controllability, mean  SD 3.0  0.7 3.0  0.7 3.0  0.8 0.365
n 800 281 519
Treatment controllability, mean  SD 3.7  0.6 3.6  0.5 3.8  0.6 £0.001
n 792 282 510
Coherence (understanding), mean  SD 3.4  0.9 3.2  0.9 3.5  0.9 £0.001
n 800 281 519
Emotional response, mean  SD 3.4  0.8 3.5  0.8 3.4  0.9 0.702
n 802 284 518
Medication beliefs (BMQ6)
Specific necessity, mean  SD 3.7  0.8 3.5  0.8 3.9  0.8 £0.001
n 795 281 514
Specific concerns, mean  SD 2.5  0.7 2.7  0.7 2.3  0.6 £0.001
n 794 280 514
(continued )
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who take medicines should stop their treatment for a while
every now and again, that most medicines “are addictive,”
“are poisons,” and “do more harm than good.”
Group 2 (61%, n ¼ 493) was labeled “side effects and
overuse.” Although patients reported weaker medicationconcerns than Group 1, they still expressed strong concerns
about potential long-term adverse effects from their systemic
therapy and concerns about the general overuse of medi-
cines. Group 3 (12.6%, n ¼ 102) was labeled “treatment
resolved”; patients reported far lower ratings for medication
concerns compared to Group 1 and 2.www.jidonline.org 787
Table 1. Continued
Characteristics
Total Sample
(n [ 811)
Conventional Cohort1
(35.3%, n [ 286)
Biologic Cohort2
(64.7%, n [ 525) P-Value3
General overuse, mean  SD 2.7  0.7 2.7  0.7 2.7  0.7 0.287
n 804 286 518
General harmfulness, mean  SD 2.3  0.6 2.3  0.6 2.2  0.6 0.029
n 802 286 516
Abbreviations: BMQ, Beliefs about Medicines Questionnaire; DLQI, Dermatology Life Quality Index; HADS, Hospital Anxiety and Depression Scale;
IPQ-R, Revised Illness Perception Questionnaire; PASI, Psoriasis Area and Severity Index; SD, standard deviation.
1Includes methotrexate, cyclosporine, acitretin, and fumaric acid esters.
2Includes adalimumab, ustekinumab, and etanercept.
3The P-value tests for significant differences between the conventional systemic and biologic cohorts using t-tests and c2 tests. Boldface indicates P < 0.05.
4Includes any of (excluding psoriatic arthritis) hypertension, angina, ischemic heart disease, stroke, epilepsy, asthma, chronic obstructive pulmonary disease,
peptic ulcer, renal disease, hepatic disease, tuberculosis, demyelinating disease, diabetes, impaired glucose tolerance, depression, non-skin cancer,
immunodeficiency syndrome, thyroid disease, other.
5The possible score range for HADS anxiety and HADS depression is 021.
6The possible score range for all IPQ-R and BMQ items (excluding illness identity) is 15.
7The possible score range for illness identity is 017.
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cation belief groups significantly differed by treatment cohort
(P  0.001), with a higher proportion of patients in the bio-
logic cohort classified into Group 3 (15.5%; n ¼ 81)
compared with the conventional cohort (7.3%; n ¼ 21).
Factors associated with non-adherence to self-administered
systemic therapies
Factors influencing non-adherence may be different for
ustekinumab (e.g., delay in administration) compared with
self-administered systemic therapies. We did not have data
on these “system” factors and for these reasons patients
prescribed ustekinumab (n ¼ 160) and those with missing
biologic treatment type (n ¼ 34) were excluded from the
analyses examining factors associated with adherence.
The results from the regression analyses are presented in
Table 3.
Overall non-adherence. The multivariable model showed
that being on a conventional systemic (odds ratio [OR] ¼
4.34, 95% CI ¼ 2.387.91), having strong medication con-
cerns (OR ¼ 1.92; 95% CI ¼ 1.093.39), weaker routine/
habit for taking their systemic therapy (OR ¼ 0.94; 95%
CI ¼ 0.910.97), longer treatment duration (OR¼ 1.04; 95%
CI ¼ 1.021.06), and younger age (OR ¼ 0.97, 95%
CI ¼ 0.950.99) were factors associated with being classified
as overall non-adherent. Together, these variables were
significantly associated with overall non-adherence (c2
[20] ¼ 73.32, P  0.001) and accounted for 23.4% of the
variability in the overall non-adherent variable.
Intentional non-adherence. Being on a conventional sys-
temic therapy (OR ¼ 3.21, 95% CI ¼ 1.546.67), having
strong medication concerns (OR ¼ 2.27, 95% CI ¼
1.164.47), weaker routine/habit for taking their systemic
therapy (OR ¼ 0.95; 95% CI ¼ 0.920.98), and longer
treatment duration (OR ¼ 1.04, 95% CI ¼ 1.011.06) were
also factors associated with intentional non-adherence. The
model was significant (c2 [20] ¼ 40.91, P ¼ 0.004) and
accounted for 17.0% of the variability in the intentionally
non-adherent variable.Journal of Investigative Dermatology (2018), Volume 138Unintentional non-adherence. Being on a conventional
systemic therapy (OR ¼ 4.87, 95% CI ¼ 2.2410.59),
stronger perceptions of psoriasis being a chronic condition
(OR ¼ 2.16, 95% CI ¼ 1.034.52), weaker routine/habit for
taking their systemic therapy (OR ¼ 0.92, 95% CI ¼
0.890.96), younger age (OR ¼ 0.95, 95% CI 0.920.98),
and longer treatment duration (OR ¼ 1.03, 95% CI ¼
1.011.06) were factors associated with unintentional non-
adherence. The model was significant (c2 [20] ¼ 65.92,
P ¼  0.001) and accounted for 26.6% of the variability in
the unintentional non-adherent variable.
DISCUSSION
Main findings
This is the largest study to assess adherence to conventional
systemic and biologic therapies used for psoriasis in a
real-world setting to date; 22.4% of patients using
self-administered systemic therapies are classified as non-
adherent, with a higher proportion of patients using a con-
ventional systemic classified as non-adherent (29.2%)
compared to those using etanercept or adalimumab (16.4%).
Patients’ medication beliefs are key drivers of intentional
non-adherence. Medication-taking routine or habit strength
influences intentional and unintentional non-adherence.
Comparison to other studies
Adherence is known to be problematic across many long-
term conditions (Nieuwlaat et al., 2014), with a recent
study in rheumatoid arthritis showing that 27% of patients
self-report non-adherence at least once within 6 months of
starting a biologic therapy (Bluett et al., 2014). Both higher
and lower levels of adherence to systemic therapies used for
psoriasis have been reported in other studies reflecting dif-
ferences in study inclusion criteria and size, and the use of
non-validated self-report tools to assess adherence
(Thorneloe et al., 2013). Previous adherence research has
focused predominantly on demographic and clinical pre-
dictors, however, these variables show weak or inconsistent
relationships with adherence in psoriasis (Thorneloe et al.,
2013) and in other long-term conditions (DiMatteo, 2004),
a finding consistent with our results. These factors are not
Table 2. Proportion of patients classified as non-adherent to self-administered systemic therapies (n [ 617)
Adherence Total Sample Conventional Cohort1 Biologic Cohort2 P-value3
Overall non-adherent, % (n) 22.4 (134) 29.2 (82) 16.4 (52) £0.001
n 599 281 318
Intentionally non-adherent, % (n) 12 (72) 15.3 (43) 9.1 (29) 0.020
n 599 281 318
Unintentionally non-adherent, % (n) 10.9 (66) 14.5 (41) 7.7 (25) 0.007
n 605 282 323
1Includes methotrexate, cyclosporine, acitretin and fumaric acid esters.
2Includes adalimumab and etanercept.
3P-value tests for significant differences between the conventional systemic and biologic cohorts using c2 tests. Boldface indicates P  0.05.
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informing adherence interventions. We have demonstrated
that different “modifiable” factors are associated with inten-
tional and unintentional non-adherence.
In other disease groups, the important influences of patients’
medication beliefs on adherence have been demonstrated
(Horne et al., 2013). We have shown that a significant pro-
portion of patients express conflicting beliefs about their sys-
temic therapy; strong beliefs in the perceived need and
effectiveness of their systemic therapy and strong concerns
about its usage. Patients were more likely to make the decision
to use their systemic therapies in ways that have not been
prescribed, such as using less of it or stopping treatment for a
while (intentional non-adherence) if they had unresolved
medication concerns. Patient understanding of the causes and
triggers of psoriasis and its disease mechanisms can be low
(Nelson et al., 2013a) and the current study suggests that this
lack of “illness coherence” may contribute to intentional non-
adherence. Patients’ understanding of psoriasis will influence
their beliefs about systemic therapies (Horne and Weinman,
2002; Nelson et al., 2017), which is likely to account for the
fact that it was not associated with intentional non-adherence
after controlling for other variables.
Some instances of intentional non-adherence may be
influenced by good disease control; patients may decide to
strategically alter their treatment regimen if their symptomsPercentage (n) classified as ove
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25.7% (18)
45.8% (27have improved. The impact of disease control on medication
non-adherence is likely to be mediated by patients’ beliefs
about their psoriasis and medication. Patients who perceive
good disease control may report reduced perceived need for
their treatment and decide to alter their treatment regimen,
especially if they also report concerns about its usage. Psy-
chological distress was not associated with non-adherence.
Although depression is a known risk factor for non-
adherence in long-term conditions (Grenard et al., 2011),
we have previously shown that distress can remain high in
psoriasis even if the patient is adhering to their treatment
(Thorneloe et al., 2017a).
In other disease groups, the strength of the patient’s
routine, or habit, for taking their medication has been shown
to predict unintentional non-adherence, such as forgetting to
use medication (Bolman et al., 2011; Phillips et al., 2013).
Habit-based interventions have been shown to be effective in
improving medication adherence (Conn et al., 2017). This
study found habit strength was associated with intentional
and unintentional non-adherence. Although medication be-
liefs were not associated with unintentional non-adherence,
stronger perceptions of psoriasis as a chronic condition
with serious consequences were significant contributors.
Future work should explore whether unresolved patient
concerns about psoriasis and medication are a barrier to
developing good medication-taking routines.8060
rall non-adherent
)
100
Figure 1. Proportion of patients
classified as overall non-adherent
within the oral conventional systemic
and self-administered biologic
cohorts. Fumaric acid esters were
excluded due to small sample size
(7%, n ¼ 19).
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790In the United Kingdom, patients generally use topical
therapies before commencing a conventional therapy
(National Institute for Health and Care Excellence, 2012).
Many patients express concerns about topical therapies and
perceive or experience poor health care support (Nelson
et al., 2013a; Nelson et al., 2013b; Thorneloe et al.,
2017a). Beliefs based on their earlier experiences can
persist (Rottman et al., 2017) and may influence patients’
behavior or lower expectations about subsequent use of
conventional therapies. Fewer patients in the conventional
cohort were classified as having positive medication beliefs
compared with those using a biologic. Differences in beliefs
rather than mode of administration may account for the dif-
ference in non-adherence between the conventional and
biologic cohorts. The vast majority of patients prescribed
ustekinumab were classified as adherent, consistent with its
high drug survival (Warren et al., 2015). Ustekinumab is
predominately nurse-administered in the United Kingdom;
although this will help support adherence patients may still
hold unresolved medication concerns or worries about their
therapy.
Implications for clinicians
Clinicians need to be aware of the possibility of non-
adherence. More than 20% of patients in this study
expressed strong beliefs in the personal need for treatment
while simultaneously reporting strong concerns about their
use of psoriasis-specific treatments, as well about use of
medicines in general. Intentional non-adherence was most
common in this group. This group may benefit most from
interventions targeting key medication beliefs (Petrie et al.,
2012; Phillips et al., 2012). The UK National Institute for
Health and Care Excellence (2009) Medicines Adherence
Guidelines provides recommendations for supporting shared
medication decision-making and adherence. Clinicians
should talk with the patient to understand their perspective
and establish key medication beliefs before prescribing new
treatments and when reviewing medicines. This can be
achieved by using standardized assessment tools, such as theJournal of Investigative Dermatology (2018), Volume 138Beliefs about Medicines Questionnaire (Horne et al., 1999)
or by asking the patient what they know, believe, and un-
derstand about their medicines, including any specific con-
cerns they may have about their medication. Doing so will
provide an opportunity for the clinician to modify incorrect
or incomplete beliefs and help support patient treatment
decision-making. Unintentional non-adherence needs an
interventional approach that focuses on developing planned
and automatic routines for medication-taking (Conn et al.,
2017; O’Carroll et al., 2014). Encouraging the patient to
discuss how medication usage fits into their daily life and any
practical barriers they may face will help to identify potential
solutions and develop good medication-taking habits and
routines.
Strengths and limitations of the study
The real-world cohort study design ensures that patients are
representative of those receiving treatment in routine clinical
practice. However, an inherent limitation to an observational
study is the potential for selection bias. Although the overall
sample size was large, 10.5% of patients were not matched to
BADBIR and were excluded from the regression models.
Adherence rates for the separate systemic therapies should be
interpreted with some caution due to smaller number of pa-
tients in these specific treatment groups and thus, we were
unable to explore why adherence varied by specific treatment
type. Ustekinumab is predominately nurse-administered in
the United Kingdom, however it is possible that some pa-
tients were self-administering. Although it is not possible to
infer causality from cross-sectional analyses, the use of
appropriate theoretical frameworks and validated data
collection tools are major strengths. Although medication
belief Groups 2 and 3 had different belief profiles, they were
combined in adherence analyses due to the small number of
cases in Group 3 being classified as non-adherent.
Self-report tools of adherence can be criticized for being
influenced by poor patient recall or reporting bias and so they
can overestimate adherence. However, they are the only
tools able to distinguish intentional and unintentional non-
adherence. The validated Medication Adherence Report
Scale has been shown to provide a good estimate of adher-
ence in other conditions (Horne and Weinman, 2002; Ohm
and Aaronson, 2006). When we use self-report measures of
adherence, it is important that we distinguish non-adherence,
where the patient themselves decide to use their treatment in
ways that have not been prescribed, from clinician-
prescribed cessation of treatment, where the clinician may
appropriately stop treatment, for example, due to an infec-
tion. We appropriately modified the Medication Adherence
Report Scale so the items referred to patient treatment
decision-making. If this confounder were present, we would
not expect a relationship between beliefs and medication-
taking habit/routine with non-adherence. Given that we
found this association, we are confident that we measured
true non-adherence, rather than appropriate clinician-
prescribed variation in treatment usage.
Summary
Significant proportions of patients with psoriasis prescribed
self-administered systemic therapies report intentional and
unintentional non-adherence with their treatment regimen.
Table 3. The univariable and multivariable regression models for non-adherence to self-administered systemic
therapies1
Variable
Overall Non-Adherent Intentionally Non-Adherent Unintentionally Non-Adherent
Univariable Multivariable Univariable Multivariable Univariable Multivariable
Demographic
Age, y 0.97 (0.96L0.99) 0.97 (0.95L0.99) 1.00 (0.981.02) 1.00 (0.971.03) 0.95 (0.93L0.97) 0.95 (0.92L0.98)
n 553 449 553 449 559 451
Male 1.32 (0.872.0) 1.67 (0.972.89) 1.11 (0.661.88) 1.39 (0.712.72) 1.03 (0.601.76) 1.26 (0.632.53)
n 553 449 553 449 559 451
Disease
Disease duration, y 0.98 (0.97L1.00) 1.01 (0.98- 1.03) 1.00 (0.981.02) 1.01 (0.991.04) 0.98 (0.961.00) 1.00 (0.971.03)
n 551 449 551 449 557 451
PASI at the start of treatment 0.98 (0.951.01) 0.97 (0.941.01) 0.98 (0.941.02) 0.96 (0.911.01) 1.01 (0.971.05) 1.00 (0.951.04)
n 531 449 531 449 537 451
DLQI at the start of treatment 1.01 (0.991.04) 1.01 (0.981.05) 1.02 (0.991.06) 1.03 (0.981.08) 1.01 (0.971.05) 0.99 (0.951.04)
n 525 449 525 449 530 451
Comorbidities
Presence of 1 comorbidity2 0.92 (0.611.41) 1.35 (0.752.41) 0.87 (0.511.49) 0.95 (0.461.96) 0.98 (0.561.72) 1.65 (0.783.49)
n 554 449 554 449 560 451
Inflammatory arthritis 0.91 (0.531.55) 1.35 (0.662.76) 1.21 (0.632.32) 1.78 (0.744.24) 1.03 (0.522.07) 1.60 (0.644.02)
n 551 449 551 449 557 451
Treatment
Treatment duration, mo 1.01 (1.001.03) 1.04 (1.02L1.06) 1.02 (1.00 - 1.03) 1.04 (1.01L1.06) 1.00 (0.991.02) 1.03 (1.01L1.06)
n 573 449 573 449 579 451
Conventional therapy 2.11 (1.42L3.12) 4.34 (2.38L7.91) 1.80 (1.09L2.97) 3.21 (1.54L6.67) 2.03 (1.20L3.43) 4.87 (2.24L10.59)
n 599 449 599 449 605 451
Psychological distress (HADS)
Anxiety 1.03 (0.981.07) 1.04 (0.951.13) 1.02 (0.971.08) 1.04 (0.931.16) 1.05 (0.991.11) 1.01 (0.911.13)
n 588 449 588 449 594 451
Depression 1.01 (0.961.06) 0.95 (0.861.04) 1.00 (0.941.06) 0.93 (0.821.04) 1.04 (0.981.10) 0.99 (0.881.12)
n 588 449 588 449 594 451
Illness beliefs and emotional response
toward psoriasis (IPQ-R)
Illness identity (symptoms) 1.04 (0.971.11) 0.99 (0.901.09) 1.071 (0.991.17) 1.06 (0.951.19) 0.98 (0.891.08) 0.88 (0.771.01)
n 579 449 579 449 585 451
Timeline acute/chronic 0.99 (0.721.36) 1.04 (0.621.72) 0.86 (0.571.28) 0.98 (0.521.85) 1.86 (1.13L3.06) 2.16 (1.03L4.52)
n 589 449 589 449 595 451
Timeline cyclical 1.19 (0.901.57) 0.94 (0.631.39) 1.28 (0.901.83) 0.97 (0.601.59) 1.06 (0.741.53) 0.80 (0.481.31)
n 594 449 594 449 600 451
Consequences 0.99 (0.761.29) 0.87 (0.501.52) 1.01 (0.721.43) 0.71 (0.351.45) 1.46 (1.00L2.11) 1.15 (0.582.30)
n 596 449 596 449 602 451
Personal controllability 1.36 (1.041.77) 1.40 (0.952.07) 1.07 (0.761.50) 1.12 (0.691.81) 1.38 (0.971.98) 1.5 (0.922.45)
n 591 449 591 449 597 451
Coherence (understanding) 0.83 (0.681.01) 0.88 (0.651.19) 0.72 (0.56L0.94) 0.85 (0.591.23) 0.92 (0.701.20) 0.78 (0.531.14)
n 591 449 591 449 597 451
Emotional response towards
psoriasis
1.03 (0.821.31) 1.18 (0.721.92) 1.19 (0.881.61) 1.52 (0.802.87) 1.12 (0.821.54) 0.95 (0.521.73)
n 595 449 595 449 601 451
Medication beliefs
Group 1 (strongly concerned)3 1.69 (1.12L2.56) 1.92 (1.09L3.39) 2.35 (1.41L3.90) 2.27 (1.16L4.47) 1.14 (0.642.0) 1.00 (0.462.16)
n 597 449 597 449 603 451
(continued )
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beliefs were associated with intentional non-adherence, with
the strength of the patients’ medication-taking routine asso-
ciated with unintentional non-adherence. This study em-
phasizes the need to assess adherence when determining
factors influencing treatment response.MATERIALS AND METHODS
Patients attending 35 dermatology clinics across England were
recruited into the iMAP study between March 2013 and September
2016. Patients with a diagnosis of psoriasis under the care of a
dermatologist, prescribed an oral conventional systemic (metho-
trexate, cyclosporine, acitretin, fumaric acid esters), and/or awww.jidonline.org 791
Table 3. Continued
Variable
Overall Non-Adherent Intentionally Non-Adherent Unintentionally Non-Adherent
Univariable Multivariable Univariable Multivariable Univariable Multivariable
Strength of the patient’s habit, or
routine, for using their prescribed
systemic therapy
Habit 0.94 (0.92L0.97) 0.94 (0.91L0.97) 0.96 (0.93L0.98) 0.95 (0.92L0.98) 0.93 (0.90L0.95) 0.92 (0.89L0.96)
n 570 449 570 449 573 451
Abbreviations: CI, confidence interval; HADS, hospital anxiety and depression scale; IPQ-R, Illness Perception Questionnaire- Revised; OR, odds ratio.
1Self-administered systemic therapies include methotrexate, cyclosporine, acitretin, fumaric acid esters, adalimumab, and etanercept. Boldface indicates
P  0.05.
2Reference category: no comorbidities (excluding psoriatic arthritis); includes any of hypertension, angina, ischemic heart disease, stroke, epilepsy, asthma,
chronic obstructive pulmonary disease, peptic ulcer, renal disease, hepatic disease, tuberculosis, demyelinating disease, diabetes, impaired glucose
tolerance, depression, non-skin cancer, immunodeficiency syndrome, thyroid disease, other.
3Reference category: Medication belief Group 2 (side effects and overuse) and Group 3 (treatment resolved).
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792subcutaneous biologic treatment (etanercept, adalimumab, usteki-
numab), aged 18 years, and enrolled on BADBIR were eligible for
inclusion into the study. In total, 811 psoriasis patients were
included in the analysis (Supplementary Figure S1 online).
Measures
Psoriasis patients were instructed to complete a questionnaire
independently and anonymously and return to the investigator. It
contained the following measures:
1. The Medication Adherence Report Scale (Horne and Weinman,
2002) that assesses the frequency of intentional (6-items) and
unintentional (2-items) non-adherent behaviors on a 5-point
Likert scale ranging from very often (¼ 1) to never (¼ 5), with
higher scores indicating higher levels of adherent behavior. It has
been modified and used extensively across many disease groups
(Horne and Weinman, 2002; Ohm and Aaronson, 2006). All
intentional items were modified to begin with the stem “I
decided” (e.g., “I decided to alter the dose of my psoriasis
injection/tablets”). Patients were classified into overall adherent/
non-adherent categories using a score of 38/40, and also clas-
sified into intentional (28/30) and unintentional (8/10) cate-
gories (Butler et al., 2004; van den Bemt et al., 2009).
2. The strength of the patient’s habit, or routine, for using their
prescribed systemic therapy was assessed using the validated
Self-Report Habit Index (Verplanken and Orbell, 2003). Each
item is scored on a 5-point Likert scale (strongly disagree [¼ 1] to
strongly agree [¼ 5]) and summed, with scores ranging from 12 to
60, with higher scores indicating stronger habit.
3. Patients’ beliefs about their psoriasis and emotional responses
toward their condition were assessed using the validated Revised
Illness Perceptions Questionnaire (Moss-Morris et al., 2002).
Seven subscales (39 items) measure perceptions of: how long
psoriasis will last (timeline acute/chronic/cyclical); consequences
associated with the condition (consequences); personal control;
treatment control; understanding of their condition (coherence);
and emotional response towards psoriasis. Each item was scored
on a 5-point Likert scale (strongly disagree [¼ 1] to strongly agree
[¼ 5]). A mean score was calculated for each subscale, ranging
from 1 to 5, with higher scores indicating stronger illness beliefs
and more negative emotional response towards psoriasis. Symp-
toms attributed to psoriasis (“illness identity”) were assessed
(17 items), with each yes-rated symptom scored and summedJournal of Investigative Dermatology (2018), Volume 138(yes [¼ 1], no [¼ 0]), ranging from 0 to 17. In line with the
previous research (Fortune et al., 1998), one psoriasis-specific
item was included in the timeline cyclical subscale (“If my pso-
riasis clears it will always come back”) and three additional
symptoms were included in the identity scale (“skin flaking,”
“burning sensations,” and “itching”).
4. The Beliefs about Medicines Questionnaire (Horne et al., 1999)
assesses: patients’ perceived need for their prescribed systemic
therapy (6-items specific-necessity); concerns about the potential
adverse consequences of taking it (five items specific-concerns);
beliefs in the general harmfulness of medication (four items
General-Harm) and; beliefs that medications are overused by
doctors (four items General-Overuse). The Beliefs about Medi-
cines Questionnaire was appropriately adapted for use in psori-
asis (Thorneloe et al., 2017b). Each item is scored on a 5-point
scale (“strongly disagree” [¼ 1] to “strongly agree” [¼ 5]), with
higher scores indicating stronger medication beliefs. A mean
score was calculated for each subscale, with scores ranging from
1 to 5.
5. The Hospital Anxiety and Depression Scale (Zigmond and Snaith,
1983) provides an assessment of symptoms of anxiety (seven
items) and depression (seven items) among patients with a
physical illness. Patients indicate the strength of agreement with
each item on a 0- to 3-point scale. Items are summed to create a
Hospital Anxiety and Depression Scale anxiety and depression
score, both ranging from 0 to 21. A score of 8 indicates a
possible or probable caseness of anxiety or depression (Bjelland
et al., 2002). Permission was granted to use the Hospital Anxi-
ety and Depression Scale.
Once patients were recruited into the iMAP study, their corre-
sponding data from BADBIR were accessed (with written informed
patient consent). Demographic (age, sex) and disease data (age of
onset, disease duration, comorbidities) recorded at BADBIR regis-
tration were extracted. Treatment variables (treatment type and
duration) were extracted at times corresponding to the dates when
patients completed the iMAP questionnaire. Psoriasis Area and
Severity Index and Dermatology Life Quality Index scores were
extracted at the time the patient started the therapy; the closest
Psoriasis Area and Severity Index and Dermatology Life Quality
Index scores recorded within 6 months of the treatment start date
(before or after) were extracted.
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Differences in baseline characteristics between the conventional
and biologic cohorts were analyzed using t-tests and c2 tests
(Tables 1 and 2). LPA was used to identify the optimal number of
medication belief groups. The Beliefs about Medicines Question-
naire subscales of specific necessity, specific concerns, general
overuse, and general harmfulness, and the Revised Illness Perception
Questionnaire subscale of treatment control, were included in the
LPA analysis. Three participants had missing data for all five vari-
ables and were excluded from the analysis. The model fit statistics
for LPA models with one through five class solutions were examined
(Supplementary Table S1). These were the Bayesian Information
Criterion, where smaller values indicate a better fit, and the Vuong-
Lo-Mendell-Rubin Likelihood ratio test and the Lo-Mendell-Rubin
Adjusted Likelihood ratio test, both of which compare the current
model to a model with one less latent class. Entropy provides a
measure of the classification quality of the model, with values
approaching 1 indicating a good separation of classes.
Three separate logistic multiple regressions were conducted
(Table 3). The odds ratios represent the effect of a 1-unit change in
the predictor; they are not standardized and their size depends
largely on the units used for the predictor variables. Medication
belief Groups 2 and 3 were combined, due to the small number of
cases in Group 3 classified as non-adherent (8 cases). LPA was
conducted in Mplus 7 (Muthe´n and Muthe´n, 19982007) and all
other analyses were conducted in SPSS, version 23 (IBM, Armonk,
NY).
Rates of missing data were very low for the Medication Adherence
Report Scale, Self-Report Habit Index, Beliefs about Medicines
Questionnaire, Revised Illness Perception Questionnaire and Hos-
pital Anxiety and Depression Scale, ranging from 0.9% to 5.3%. A
small number of patients were unable to be matched with data
drawn from the registry (Supplementary Figure S1), the amount of
missing data was higher for variables obtained from BADBIR,
ranging from 6% to 15.7%.
Ethical approval
Ethical approval for iMAP was obtained from NHS Research Ethics
Committee North West England (reference 12/NW/0619) in
December 2012 (and from research ethics committees local to each
recruiting site). All subjects gave written informed patient consent
prior to data collection.
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